GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ABUS · Dec 31, 2025

Arbutus Biopharma Corp. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001447028-26-000017General Corporate
Debt relative to revenue100thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.debt_to_revenue

0.00% · OPTIONAL · VALID

Capex intensity33thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

0.00% · OPTIONAL · VALID

Operating cash generation83thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-281.45% · OPTIONAL · VALID

Revenue growth88thOwn-history percentile · N=8
Evidence method

Yoy · gp.fundamentals.revenue

128.21% · CORE · VALID

Operating margin75thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.operating_margin

-270.96% · CORE · VALID

R&D intensity8thOwn-history percentile · N=12
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

179.23% · OPTIONAL · VALID

SBC intensity25thOwn-history percentile · N=12
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

49.37% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building
Dec 31, 20230/7 normalizedLevel 3Mar 31, 20240/7 normalizedLevel 3Jun 30, 20240/7 normalizedLevel 3Sep 30, 20240/7 normalizedLevel 3Dec 31, 20246/7 normalizedLevel 3Mar 31, 20256/7 normalizedLevel 3Jun 30, 20256/7 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20257/7 normalizedLevel 3Mar 31, 20266/6 normalizedLevel 3Jun 30, 20266/6 normalizedLevel 3
Period transition

What moved in the state?

Cash Generation Increased
Previous
-1099.62%
Current
-281.45%
Delta
818.17%
Growth Increased
Previous
-60.49%
Current
128.21%
Delta
188.71%
Profitability Increased
Previous
-1636.86%
Current
-270.96%
Delta
1365.90%
R And D Intensity Decreased
Previous
1092.25%
Current
179.23%
Delta
-913.02%
Sbc Intensity Decreased
Previous
227.22%
Current
49.37%
Delta
-177.85%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ABUS Fundamental State →Transitioned To · ABUS GROWTH_INCREASED →Transitioned To · ABUS PROFITABILITY_INCREASED →Transitioned To · ABUS R_AND_D_INTENSITY_DECREASED →Transitioned To · ABUS SBC_INTENSITY_DECREASED →Transitioned To · ABUS Fundamental State →Transitioned To · ABUS CASH_GENERATION_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.